Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "SUIT-003 O2 ce D061"

From Bioblast
Line 1: Line 1:
{{MitoPedia
{{MitoPedia
|abbr=ce
|abbr=Carrier control of the plasma membrane-permeable succinate ([[MitoKit-CII/Succinate-nv]]) and plasma membrane-permeable malonate ([[MitoKit-CII/Malonate-nv]]] - [[SUIT-003 O2 ce D060]]
|description=[[File:Ce1;ce2Omy;ce3U;ce4Rot;ce5S;ce6Mnanv;ce7Ama.png|400px]]
|description=[[File:ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama.png|400px]]
|info='''B''' -Β  complex cell [[coupling control protocol]] (CCP) with the Prodrug of malonate [[NV161/MitoKit-CII|NV161]]-'''[[SUIT-003]]'''
|info='''B''' Β 
|application=O2
|application=O2
|SUIT number=D061_ce1;ce2Omy;ce3U;ce4Rot;ce5S;ce6Mnanv;ce7Ama
|SUIT number=D061_ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama
}}
}}
::: '''[[MitoPedia: SUIT]]''' - Coupling control protocol (CCP) with the carrier of the plasma membrane-permeable succinate (MitoKit-CII/Succinate-nv) and plasma membrane-permeable malonate (MitoKit-CII/Malonate-nv] in living cells (ce): DMSO.
::: '''[[SUIT protocol pattern]]:''' ce1;(ce2Omy);ce3U;ce4DMSO;ce5DMSO;ce6Rot;ce7Ama


SUIT-003 O2 ce-pce D061 is designed to study [[coupling control state| coupling control]] and the presence of succinate transporters in the plasma membrane of living cells. Respiratory capacities are tested in a sequence of coupling states: [[ROUTINE]], [[LEAK]] and [[ET]]. To study [[LEAK-respiration]], the [[phosphorylation system]] is inhibited by [[oligomycin]]. The final concentration of [[oligomycin]] has to be carefully optimized for various cell types, to minimize the inhibitory effect on the [[Electron transfer-pathway|electron transfer system]] which would lead to an underestimation of [[ET-capacity]]. The addition of succinate after rotenone will allow us to stimulate the respiration in living cells expressing a succinate transporter in the plasma membrane and those cells that present a damage plasma membrane and are permeable to the substrate. However, the use of the [[NV161/MitoKit-CII| Prodrug of malonate (Mnanv)]] allows us to differentiate between these two possible sources of stimulation in the respiration. The permeable compounds only work in living cells which a non-altered plasma membrane due that to be active the cytosolic esterases must cleavage the compound. The living cells with an altered permeability of the plasma membrane will not be affected by the used of the [[NV161/MitoKit-CII| Prodrug of malonate (Mnanv)]].
SUIT-003 O2 ce D061 protocol is the control of the [[SUIT-003 O2 ce D060]] adding the [[Carrier control titrations|carrier]] DMSO in [[ROX]] instead of the plasma membrane-permeable succinate ([[MitoKit-CII/Succinate-nv]])and plasma membrane-permeable malonate ([[MitoKit-CII/Malonate-nv]]]. Moreover,the SUIT-003 O2 ce D061 protocol allows to evaluate the [[coupling control state |coupling control]] of living cells. Respiratory capacities are tested in a sequence of coupling states: [[ROUTINE]] and [[ET]]. Optionally, to study [[LEAK-respiration]], the [[phosphorylation system]] might be inhibited by [[oligomycin]]. The final concentration of [[oligomycin]] has to be carefully optimized for various cell types, to minimize the inhibitory effect on the [[Electron transfer-pathway|electron transfer system]] which would lead to an underestimation of [[ET-capacity]]. Β 




Line 16: Line 18:


== Strengths and limitations ==
== Strengths and limitations ==
:::* The [[SUIT-003 O2 ce D061]] is a cell [[coupling control protocol]]. The total cell count (''N''<sub>ce</sub>) is the sum of viable cells (''N''<sub>vce</sub>) and dead cells (''N''<sub>dce</sub>).
:::* [[CIV]] activity can also be measured after the cell viability test module.
:::* [[CIV]] activity can also be measured after the cell viability test module.
:::- The addition of [[oligomycin]] has to be carefully tested to avoid inhibitory effects in the evaluation of the [[ET-capacity]].
:::- The addition of [[oligomycin]] has to be carefully tested to avoid inhibitory effects in the evaluation of the [[ET-capacity]].
:::- Careful washing is required after the experiment to avoid carry-over of inhibitors and uncoupler.
Β 




== Compare SUIT protocols ==
== Compare SUIT protocols ==
::::* [[SUIT-003 O2 ce D060]] CCP with cell permeable compounds [[NV118/MitoKit-CII|NV118]] and [[NV161/MitoKit-CII|NV161]]
::::* [[SUIT-003 O2 ce D060]] CCP with plasma membrane-permeable compounds [[MitoKit-CII/Succinate-nv]] and [[MitoKit-CII/Malonate-nv]].
::::* [[SUIT-003 O2 ce D028]] for cell membrane permeability test CCP(S).
::::* [[SUIT-003 O2 ce D028]] for cell membrane permeability test CCP(S).
::::* [[SUIT-003 O2 ce-pce D013]] first version of the Coupling control protocol and respirometric cell viability test (CCV protocol).
::::* [[SUIT-003 O2 ce-pce D013]] first version of the Coupling control protocol and respirometric cell viability test (CCV protocol).

Revision as of 12:06, 26 June 2019


high-resolution terminology - matching measurements at high-resolution


SUIT-003 O2 ce D061

Description

Ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama.png

Abbreviation: Carrier control of the plasma membrane-permeable succinate (MitoKit-CII/Succinate-nv) and plasma membrane-permeable malonate (MitoKit-CII/Malonate-nv] - SUIT-003 O2 ce D060

Reference: B

SUIT number: D061_ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama

O2k-Application: O2

MitoPedia: SUIT - Coupling control protocol (CCP) with the carrier of the plasma membrane-permeable succinate (MitoKit-CII/Succinate-nv) and plasma membrane-permeable malonate (MitoKit-CII/Malonate-nv] in living cells (ce): DMSO.
SUIT protocol pattern: ce1;(ce2Omy);ce3U;ce4DMSO;ce5DMSO;ce6Rot;ce7Ama

SUIT-003 O2 ce D061 protocol is the control of the SUIT-003 O2 ce D060 adding the carrier DMSO in ROX instead of the plasma membrane-permeable succinate (MitoKit-CII/Succinate-nv)and plasma membrane-permeable malonate (MitoKit-CII/Malonate-nv]. Moreover,the SUIT-003 O2 ce D061 protocol allows to evaluate the coupling control of living cells. Respiratory capacities are tested in a sequence of coupling states: ROUTINE and ET. Optionally, to study LEAK-respiration, the phosphorylation system might be inhibited by oligomycin. The final concentration of oligomycin has to be carefully optimized for various cell types, to minimize the inhibitory effect on the electron transfer system which would lead to an underestimation of ET-capacity.


Communicated by  Garcia-Souza LF and Gnaiger E(last update 2019-06-26)
MitoPedia: SUIT

Steps and respiratory states

Ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama.png

Step State Pathway Q-junction Comment - Events (E) and Marks (M)
ce1 ROUTINE ce1
  • ROUTINE respiration in the physiological coupling state R. Externally added permeable substrates could contribute to this respiratory state.


(ce2Omy) L(Omy) ce1;(ce2Omy)
  • Non-phosphorylating resting state (LEAK state); LEAK-respiration, L(Omy), after blocking the ATP synthase with oligomycin.
  • The addition of oligomycin is optional depending on the experimental question to resolve.
ce3U E cce1;(ce2Omy);ce3U
ce4Rot ROX ce1;(ce2Omy);ce3U;ce4Rot
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.
ce5DMSO ROX ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.
ce6DMSO ROX ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.
ce7Ama ROX ce1;(ce2Omy);ce3U;ce4Rot;ce5DMSO;ce6DMSO;ce7Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.

Strengths and limitations

  • CIV activity can also be measured after the cell viability test module.
- The addition of oligomycin has to be carefully tested to avoid inhibitory effects in the evaluation of the ET-capacity.


Compare SUIT protocols


References

MitoPedia concepts: SUIT protocol, SUIT B, Find 


MitoPedia methods: Respirometry